First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States

Breast Cancer Research and Treatment · Published 2026-08-01 · DOI 10.1007/s10549-026-08040-1

Free full text

Authors (10)

Tiffany A. Traina, Elizabeth Serra, Jerome Bedard, Mohira Levesque-Leroux, Patrick Gagnon-Sanschagrin, Annie Guérin, Silke Guenther, George Joseph, Victoria Guan, Jonathan Salcedo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Traina, T., Serra, E., Bedard, J., et al. (2026). First-line treatment patterns and real-world survival outcomes in PD-L1-negative locally recurrent inoperable or metastatic triple-negative breast cancer in the United States. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08040-1

Related articles

• Real-World Survival and Treatment Regimens Across First- to Third-Line Treatment for Advanced Triple-Negative Breast Cancer · Breast Cancer: Basic and Clinical Research · 2023 · Cites or is cited by this article
• New Treatment Approaches for Triple-Negative Breast Cancer · American Society of Clinical Oncology Educational Book · 2025 · Cites or is cited by this article
• Retrospective study on regional nodal irradiation after omission of axillary lymph node dissection in sentinel lymph node-positive breast cancer: a propensity score matching analysis · Breast Cancer Research and Treatment · 2026 · Same journal
• Factors influencing discussion duration in breast cancer multidisciplinary team meetings: insights for streamlining care · Breast Cancer Research and Treatment · 2026 · Same journal
• Antacid co-treatment and pregnane X receptor genetic polymorphisms are survival determinants in patients treated with palbociclib · Breast Cancer Research and Treatment · 2026 · Same journal
• Curative-intent stereotactic ablative body radiation, surgery, and systemic therapy in non-osseous oligometastatic breast cancer · Breast Cancer Research and Treatment · 2026 · Same journal
• Early first-line systemic anticancer therapeutic attrition after metastatic recurrence in triple-negative breast cancer following neoadjuvant chemo-immunotherapy: a multicenter real-world study · Breast Cancer Research and Treatment · 2026 · Same journal
• Abemaciclib rechallenge after progression on abemaciclib plus endocrine therapy in patients with hormone receptor-positive HER2-negative metastatic breast cancer: results from the phase II again study (WJOG14220B) · Breast Cancer Research and Treatment · 2026 · Same journal
• Age-stratified difference in patient-reported health-related quality of life following breast cancer surgery · Breast Cancer Research and Treatment · 2026 · Same journal
• Rediscovering the Ciucci pathway: in-vivo evidence of a palmar lymphatic channel · Breast Cancer Research and Treatment · 2026 · Same journal